IssuerAnnouncementDetailsV2Portlet
Actions
Jamjoom Pharmaceuticals Factory Company announces obtaining approval from Saudi Food and Drug Authority (SFDA) to register its new Sterile Facility (ophthalmic products) in Jeddah
| Element List | Explanation |
|---|---|
| Announcement Detail | Jamjoom Pharmaceuticals Factory Company is pleased to announce the issuance of the Saudi Food and Drug Authority’s (SFDA) approval to register the new Sterile Facility (ophthalmic products) in Jeddah. The state-of-the-art facility is built on an area of 7,500 sqm in phase 5 of the Jeddah Industrial District, and costs approximately SAR 200 million in construction The facility specializes in producing sterile products (ophthalmic products), and its annual production capacity will reach 25 million units at full operations. Commercial production at this facility will commence once the relevant products approvals have been obtained from the SFDA. In case of any inquiries, please feel free to contact the Investor Relations department via email: ir@jamjoompharma.com |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Share
Company Performance
Key Parameters
Last Price 155.7
Net Change -0.3 (-0.19%)
Value Traded (Sar) 4,088,338
Volume Traded 26,221
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions